139 related articles for article (PubMed ID: 37343780)
21. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
22. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
23. A review of immune checkpoint blockade in breast cancer.
Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
[TBL] [Abstract][Full Text] [Related]
24. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
Wang X; Li X; Ito A; Sogo Y; Ohno T
Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
[TBL] [Abstract][Full Text] [Related]
25. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
26. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Tambunlertchai S; Geary SM; Naguib YW; Salem AK
AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
[TBL] [Abstract][Full Text] [Related]
27. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
28. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
29. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
30. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
31. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.
Liu Y; Crowe WN; Wang L; Petty WJ; Habib AA; Zhao D
Nano Res; 2023 Apr; 16(4):5300-5310. PubMed ID: 37228440
[TBL] [Abstract][Full Text] [Related]
32. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
33. Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy.
Fu Y; Huang Y; Li P; Wang L; Tang Z; Liu X; Bian X; Wu S; Wang X; Zhu B; Yu Y; Jiang J; Li C
Nano Lett; 2023 Feb; 23(4):1424-1434. PubMed ID: 36779813
[TBL] [Abstract][Full Text] [Related]
34. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
35. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
[TBL] [Abstract][Full Text] [Related]
36. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
37. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
38. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
39. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
40. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
